Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination-case report.
Urbanska EM, Grauslund M, Berger SMS, Costa JC, Koffeldt PR, Sørensen JB, Santoni-Rugiu E. Urbanska EM, et al. Transl Lung Cancer Res. 2024 Sep 30;13(9):2453-2462. doi: 10.21037/tlcr-24-439. Epub 2024 Sep 26. Transl Lung Cancer Res. 2024. PMID: 39430327 Free PMC article.
A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement.
Hu W, Zhao J, Wang G, Wang Q, Deng M, Shen J, Hofman P, Urbanska EM, Santoni-Rugiu E, Christopoulos P, Ramirez RA, Hida T, Lu X, He B. Hu W, et al. Among authors: urbanska em. Transl Lung Cancer Res. 2024 May 31;13(5):1150-1162. doi: 10.21037/tlcr-24-352. Epub 2024 May 24. Transl Lung Cancer Res. 2024. PMID: 38854939 Free PMC article.
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E, Grauslund M, Melchior LC, Costa JC, Sørensen JB, Urbanska EM. Santoni-Rugiu E, et al. Among authors: urbanska em. Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1. Lung Cancer. 2017. PMID: 29110841 Free article.
Clinical outcomes of ALK+ non-small cell lung cancer in Denmark.
Hansen KH, Johansen JS, Urbanska EM, Meldgaard P, Hjorth-Hansen P, Kristiansen C, Stelmach M, Santoni-Rugiu E, Ulhøi MP, Dydensborg AB, Dünweber C, Andersen JL. Hansen KH, et al. Among authors: urbanska em. Acta Oncol. 2023 Dec;62(12):1775-1783. doi: 10.1080/0284186X.2023.2263153. Epub 2023 Nov 25. Acta Oncol. 2023. PMID: 37815923 Free article.
Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile.
Sørensen JB, Santoni-Rugiu E, Urbanska EM. Sørensen JB, et al. Among authors: urbanska em. Chin Clin Oncol. 2024 Dec;13(6):88. doi: 10.21037/cco-24-19. Epub 2024 Aug 22. Chin Clin Oncol. 2024. PMID: 39260433 Free article. No abstract available.
91 results